CG Oncology Looks Attractive At Current Prices (Rating Upgrade)
CG Oncology, Inc.'s promising bladder cancer therapy has strong clinical results, competitive CR rates, and a $69 target ...
Red Cat: Overlooked Drone Opportunity
M revenue in 2025 with strong margins, military contracts, and Palantir collaboration. Click to read why RCAT is a Strong Buy ...
DPG Vs. DNP: A Swap Could Make Sense
Discover why DNP's reliable distributions attract income investors and explore why DPG might be a smarter buy right now.
CoreWeave's Post-IPO: Here's What You Need To Know
CoreWeave’s 2022 to 2024 financial path is one of hypergrowth, efficiency improvement, and early-stage profitability. In 2022 ...
The Potential Impact Of Tariffs On Interest Rates
Will tariffs cause inflation and higher interest rates? Jitania Kandhari discusses how subsidies, sanctions & security ...
Should You Buy BB Seguridade For Its 9% Yield?
BB Seguridade Participações S.A. offers a 9% dividend yield but is overvalued. Click for my look at BBSEY stock and its big ...
Opinion
Exxon Mobil: Keep Your Expectations Low In 2025
Exxon Mobil's stock remains steady year-over-year. Learn why the recent price rise may not last and explore its long-term growth potential in the energy sector. Read why XOM stock is a hold.